{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:34Z","timestamp":1791410794761,"version":"4.3.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023965","name":"Bob Champion Cancer Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104678","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:28:44Z","timestamp":1753892924000},"page":"104678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3954-2806","authenticated-orcid":false,"given":"David","family":"Dearnaley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.canrad.2025.104678_bib0225","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.canrad.2025.104678_bib0230","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104678_bib0235","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","article-title":"Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK\/06\/016)","volume":"4","author":"Staffurth","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6_Suppl.","key":"10.1016\/j.canrad.2025.104678_bib0240","first-page":"306","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104678_bib0245","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2019.10.017","article-title":"A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer","volume":"142","author":"Murray","year":"2020","journal-title":"Radiother Oncol"},{"issue":"17","key":"10.1016\/j.canrad.2025.104678_bib0285","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104678_bib0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0295","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2023.05.014","article-title":"Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the Prostate Cancer Study-5, a Groupe de radio-oncologie g\u00e9nito-urinaire de Qu\u00e9bec led phase 3 trial","volume":"118","author":"Niazi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.canrad.2025.104678_bib0350","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.canrad.2025.104678_bib0300","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20.","key":"10.1016\/j.canrad.2025.104678_bib0305","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104678_bib0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0315","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104678_bib0320","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.canrad.2025.104678_bib0325","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104678_bib0330","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/COC.0000000000000325","article-title":"Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial","volume":"41","author":"Hoffman","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"10.1016\/j.canrad.2025.104678_bib0335","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.19.01485","article-title":"Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer","volume":"38","author":"Avkshtol","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0340","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ijrobp.2016.12.034","article-title":"Long-term patient-reported outcomes from a phase 3 randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer","volume":"97","author":"Shaikh","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2005.01.005","article-title":"Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial","volume":"75","author":"Yarnold","year":"2005","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0255","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104678_bib0260","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","article-title":"The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgro*up analysis of the CHHiP trial","volume":"100","author":"Wilson","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104678_bib0265","series-title":"Prostate cancer: diagnosis and management (NG131)","year":"2021"},{"issue":"5","key":"10.1016\/j.canrad.2025.104678_bib0270","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104678_bib0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bju.16133","article-title":"International Society of Urological Pathology (ISUP) Gleason grade groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial","volume":"133","author":"Dearnaley","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2025.104678_bib0280","doi-asserted-by":"crossref","first-page":"104436","DOI":"10.1016\/j.ebiom.2023.104436","article-title":"Multicandidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation","volume":"88","author":"Wilkins","year":"2023","journal-title":"Ebiomedicine"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0345","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2010.03.020","article-title":"The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995","volume":"96","author":"Thames","year":"2010","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0365","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104678_bib0370","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2020.12.041","article-title":"Estimates of alpha\/beta (a\/b) ratios for individual late rectal toxicity endpoints: an analysis of the CHHiP trial","volume":"110","author":"Brand","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104678_bib0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: analysis of alpha\/beta (a\/b) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104678_bib0380","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COC.0000000000000285","article-title":"Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities","volume":"41","author":"Zaorsky","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0385","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.canrad.2025.104678_bib0390","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104678_bib0395","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104678_bib0400","doi-asserted-by":"crossref","first-page":"110568","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104678_bib0405","series-title":"EAU\u00a0\u2013\u00a0EANM\u00a0\u2013\u00a0ESTRO\u00a0\u2013\u00a0ESUR\u00a0\u2013\u00a0ISUP\u00a0\u2013\u00a0SIOG Guidelines on Prostate Cancer","author":"Mottet","year":"2023"},{"issue":"1","key":"10.1016\/j.canrad.2025.104678_bib0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.canrad.2025.104678_bib0415","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14737140.2018.1477595","article-title":"How will the CHHiP trial affect the future of prostate radiotherapy?","volume":"18","author":"Dearnaley","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.canrad.2025.104678_bib0420","doi-asserted-by":"crossref","first-page":"8170428","DOI":"10.1155\/2019\/8170428","article-title":"The financial impact of hypofractionated radiation for localized prostate cancer in the United States","volume":"2019","author":"Moore","year":"2019","journal-title":"J Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104678_bib0425","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104678_bib0430","doi-asserted-by":"crossref","first-page":"e079072","DOI":"10.1136\/bmj-2023-079072","article-title":"Using hypofractionation to decarbonise radiation oncology","volume":"386","author":"Bhatia","year":"2024","journal-title":"BMJ"},{"issue":"10196","key":"10.1016\/j.canrad.2025.104678_bib0435","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.canrad.2025.104678_bib0440","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:40:20Z","timestamp":1762368020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825000940"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104678","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104678"}}